China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999)

Equity Research Report　|　Industry: Pharmaceutical Manufacturing (TCM OTC and Consumer Health)　|　Report Date: September 13, 2026　|　As of the September 11, 2026 close; September 12–13, 2026 were weekend market holidays.

This report was automatically compiled by AI based on publicly available information and is for reference only. It does not constitute investment advice.

1. Executive Summary

China Resources Sanjiu’s first half of 2026 was characterized by “low revenue growth, earnings pressure and a business-mix transition”: operating revenue reached RMB 15.014 billion, up 1.37% year on year; net profit attributable to shareholders was RMB 1.671 billion, down 7.96%; CHC self-medication revenue was approximately RMB 6.132 billion, down 23.29%, while prescription-drug revenue was approximately RMB 6.876 billion, up 42.14%. Current growth is mainly dependent on prescription drugs and the consolidation of Tasly. The recovery of the traditional CHC business will be key to future earnings elasticity.

In 2025, the company recorded operating revenue of RMB 31.603 billion, up 14.43% year on year, while net profit attributable to shareholders increased only 1.58% to RMB 3.421 billion. Recurring net profit attributable to shareholders increased 0.52%, reflecting the constraints on profit realization from the consolidation of Tasly, M&A integration, R&D and marketing investment. The company remains centered on high-margin branded OTC and prescription drugs. In 2025, pharmaceutical manufacturing accounted for 86.08% of revenue and had a gross margin of 60.40%. The company also possesses integrated capabilities in Chinese medicinal-material quality control, national retail and hospital channels, formula granules and traditional Chinese medicine products.

The company continues to advance its R&D and platform-based strategy. R&D expenditure was RMB 731 million in the first half of 2026. It had 55 innovative and improved new drugs under development, including 7 at the NDA/Pre-NDA stage and 21 in Phase II or Phase III clinical development. The “one core, two wings” strategy and synergies among Tasly and Kunming Pharmaceutical are expected to support long-term product-mix upgrades. However, the relevant R&D and integration information has not yet translated into new orders or explicit earnings commitments.

As of September 11, 2026, the share price was RMB 23.89, with a trailing P/E of approximately 12.13x and a P/B ratio of approximately 1.74x. Valuation was relatively low, but technical momentum remained weak: the share price was below the MA5, MA10 and MA20. Short-term moving-average resistance was approximately RMB 24.45–24.55, while RMB 23.65–23.70 near the lower Bollinger Band formed a support-monitoring zone. The decline was accompanied by higher turnover and net outflows from extra-large orders, indicating continued market caution regarding earnings pressure and the business transition.

2. Company Overview

2.1 Basic Information

2.2 Main Businesses and Product Portfolio

• Self-medication and CHC healthcare products: Revenue was RMB 15.111 billion in 2025, accounting for 47.82% of operating revenue, with a gross margin of 61.67%. Products mainly cover cold and respiratory illnesses, gastrointestinal, dermatological, orthopedic, pediatric, gynecological, hepatobiliary, cardiovascular and cerebrovascular conditions, as well as consumer healthcare products. Representative brands and products include 999 Ganmaoling, Sanjiu Weitai, Shunfeng, Tianhe Gutong and Aonuo calcium products.
• Prescription drugs: Revenue was RMB 12.094 billion in 2025, accounting for 38.27% of operating revenue, with a gross margin of 58.81%. Products cover cardiovascular and metabolic diseases, oncology, respiratory diseases, neuropsychiatry, gastroenterology, orthopedics and anti-infectives. Representative products include Compound Danshen Dripping Pills, Xuesaitong Notoginseng products, Yangxue Qingnao Granules, Shenfu Injection, Huachansu, recombinant human urokinase for injection and ceftobiprole medocaril sodium.
• Kunming Pharmaceutical and traditional Chinese medicine products: Mainly contributes notoginseng products, premium traditional Chinese medicine and traditional TCM brands, with a focus on notoginseng products and the senior-health industry.
• TCM formula granules and decoction pieces: The company addresses these markets through 999 TCM formula granules and “Sanjiu Bencao Wu” premium decoction pieces, emphasizing authentic medicinal materials, origin identification, quality evaluation and end-to-end traceability.
• Pharmaceutical, medical-device wholesale and retail: Revenue was RMB 3.897 billion in 2025, accounting for 12.33% of operating revenue, with a gross margin of 14.29%; profitability is more dependent on scale and turnover.
• Packaging and printing: Revenue was RMB 501 million in 2025, accounting for 1.59% of operating revenue.
• 2025 business-caliber note: The company brought Tasly into its controlling scope and adjusted its product-level statistical methodology. Growth rates by product in 2025 and 2024 therefore cannot be interpreted simply as the natural growth of the legacy businesses.

2.3 Position in the Upstream and Downstream Industrial Chain and Cost-Profit Structure

China Resources Sanjiu occupies a relatively strong midstream position in the TCM and consumer healthcare value chain, extending upstream into Chinese medicinal-material resource control and downstream into branded, retail and hospital channels. Its core capability is not simply low-cost manufacturing, but an integrated system encompassing brands, channels, R&D, quality control and scaled manufacturing.

• Key purchases include Chinese medicinal materials and decoction-piece raw materials, materials related to TCM formula granules, chemical APIs, pharmaceutical excipients, syrup, starch, packaging materials, and specialized materials required for injections, dripping pills and tablets. The company also purchases certain finished products and uses contract-manufacturing services.
• In 2025 pharmaceutical-industry operating costs, raw-material costs were RMB 7.424 billion, accounting for 68.91%; labor costs accounted for 7.92% and manufacturing expenses for 16.85%. Raw-material prices, medicinal-material quality and production processes are the core cost variables.
• The company reduces the impact of Chinese medicinal-material price and quality fluctuations through centralized procurement, strategic reserves, supplier audits, medicinal-material base construction and origin processing. However, ordinary Chinese medicinal materials are subject to seasonality, origin differences and price volatility, and the company is not, in an absolute sense, a price setter.
• Purchases from the five largest suppliers in 2025 totaled RMB 1.319 billion, accounting for 4.93% of annual total purchases; the largest supplier accounted for 1.46%. These figures reflect the 2025 disclosure basis and indicate a relatively dispersed supplier structure and limited dependence on any single supplier, but they do not support the conclusion that the company has strong bargaining power over all raw-material suppliers.
• The company promotes seed-source control, standardized cultivation, origin processing, storage and quality traceability for authentic medicinal materials. Public information indicates that 24 authentic varieties passed extended GAP inspections. Their main functions are to ensure stable quality, reduce supply-interruption risk and strengthen procurement and process control, rather than create mineral-like resource reserves.
• CHC products are mainly sold through distributors, chain pharmacies, e-commerce platforms and O2O channels. The Sanjiu Shangdao system covers more than 600,000 pharmacies nationwide and cooperates with JD Pharmacy, AliHealth Pharmacy and Ping An Good Doctor, among others.
• Prescription drugs are mainly sold to tertiary and secondary hospitals, primary medical institutions and other medical terminals through clinical evidence, academic promotion and hospital access.
• Sales to the five largest customers in 2025 totaled RMB 4.134 billion, accounting for 13.08% of annual sales, down from 18.26% in 2024; the largest customer accounted for 5.13%. The five largest customers included Guangzhou Pharmaceutical Co., Ltd., Yunnan Pharmaceutical Co., Ltd., Jointown Pharmaceutical Group, China Resources Hunan Pharmaceutical and Shandong Jointown. These figures are based on the 2025 annual-report disclosure, primarily reproduced from annual-report announcements. No other independent sources were provided in the research notes for cross-verification; the latest annual report shall prevail.
• China Resources Hunan Pharmaceutical is a related party. Related-party sales accounted for 1.79% of annual sales in 2025. The overall proportion of the five largest customers was not high, but this indicator does not represent the concentration of all downstream terminal customers.
• Strong branded OTC products have a certain pull with consumers and retail terminals. Hospital prescription drugs face pricing pressure from medical-insurance cost controls, volume-based procurement and DRG/DIP payment reforms. Chain pharmacies and large pharmaceutical distributors may create pressure on promotions, marketing, channel expenses and payment terms.
• The pharmaceutical distribution business had a gross margin of only 14.29% and is closer to a scale- and turnover-driven business. Its bargaining power is materially weaker than that of branded pharmaceutical products.
• As of December 31, 2025, the carrying value of accounts receivable was RMB 8.164 billion, approximately 25.8% of 2025 operating revenue. Receivables due within one year were approximately RMB 7.672 billion, representing about 88.3% of the carrying balance. Accounts payable were approximately RMB 2.493 billion, or about 7.9% of operating revenue; contract liabilities were approximately RMB 1.783 billion, or about 5.6% of operating revenue. Bad-debt losses on accounts receivable were approximately RMB 36.53 million in 2025. The sizable receivables balance reflects working-capital occupation by pharmaceutical distribution, hospitals and terminal settlements, while contract liabilities provide some support for cash flow. The above data come from the audited 2025 annual report and financial notes. Accounts receivable were affected by changes in the consolidation scope following the inclusion of Kunming Pharmaceutical and Tasly; historical comparisons should use consistent consolidation bases.
• In 2025, the five largest suppliers accounted for 4.93% of purchases and the largest supplier for 1.46%; the five largest customers accounted for 13.08% of sales and the largest customer for 5.13%. Neither supplier nor customer concentration was high, but these figures cover only the 2025 disclosure basis and cannot directly demonstrate the company’s overall bargaining power with all suppliers or downstream terminals.

China Resources Sanjiu occupies a relatively strong midstream position in the “Chinese medicinal-material resource control—modern pharmaceuticals—branded OTC and hospital channels” value chain, combining upstream resource synergies with downstream brand and channel capabilities. It is neither purely a resource company nor purely a distribution company. Profit improvement will mainly depend on a recovery in CHC growth, upgrades to the prescription-drug mix, synergies with Tasly and Kunming Pharmaceutical, volume growth in formula granules and premium decoction pieces, and cost control through procurement and intelligent manufacturing.

3. Financial Data and Valuation Analysis

3.1 Recent Operating Performance

First-half 2026 data come from the formal interim report. Net profit attributable to shareholders was RMB 1.671 billion, down 7.96% year on year; the earlier earnings preview disclosed RMB 1.672 billion and a 7.90% decline. The formal interim report should be treated as the final basis. Recurring net profit attributable to shareholders in the first half of 2026 was RMB 1.597 billion, down 5.93%; basic EPS was RMB 1.00, down 8.26%; net cash flow from operating activities was RMB 2.423 billion, down 15.29%; gross margin was 56.79%, net margin approximately 13.33%, weighted average ROE 7.43%, period-end net assets per share attributable to shareholders approximately RMB 13.72, and period-end asset-liability ratio approximately 29.92%. Recurring net profit attributable to shareholders in 2025 was RMB 3.134 billion, up 0.52%; basic EPS was RMB 2.06; net cash flow from operating activities was RMB 5.513 billion, up 25.23%; weighted average ROE was 16.07%.

The first half of 2026 featured low revenue growth, earnings pressure and relatively rapid prescription-drug growth. Net profit attributable to shareholders recovered year on year in the second quarter, showing signs of earnings repair, although quarterly revenue still declined year on year. First-half CHC self-medication revenue was approximately RMB 6.132 billion, down 23.29%, while prescription-drug revenue was approximately RMB 6.876 billion, up 42.14%. CHC gross margin was approximately 61.25%, and prescription-drug gross margin approximately 64.62%. Revenue growth mainly depended on prescription drugs and the consolidation of Tasly, while the traditional CHC business came under clear pressure. Revenue growth in 2025 was mainly driven by the consolidation of Tasly, but net-profit growth was materially below revenue growth, reflecting the effects of M&A integration, expense investment and changes in profitability structure.

3.2 Earnings Forecasts

The above represents a summary of earnings forecasts from approximately 16 institutions over the six months to around September 10, 2026, as shown by Tonghuashun F10. The number of institutions on the summary page does not fully match the number shown in the detailed display. It should therefore be regarded as a summary of sell-side forecasts rather than a strictly consistent formal market consensus. Forecasts for 2026 net profit attributable to shareholders range from approximately RMB 3.190 billion to RMB 4.020 billion, with EPS forecasts ranging from approximately RMB 1.92 to RMB 2.42. Forecasts for 2027 net profit attributable to shareholders range from approximately RMB 3.688 billion to RMB 4.531 billion, and those for 2028 range from approximately RMB 3.998 billion to RMB 5.479 billion.

3.3 Valuation and Institutional Ratings

At the September 11, 2026 close, the share price was approximately RMB 23.89, total market capitalization approximately RMB 39.76 billion and P/B approximately 1.74x. Based on the 2025 annual report and 2026 interim report, trailing 12-month net profit attributable to shareholders was estimated at approximately RMB 3.277 billion, calculated as 2025 full-year net profit of RMB 3.421 billion minus first-half 2025 net profit of RMB 1.815 billion plus first-half 2026 net profit of RMB 1.671 billion. On this basis, trailing P/E was estimated at approximately 12.1x. As a cross-check, Dawave showed a trailing P/E of approximately 12.65x and P/B of approximately 1.81x at a share price of RMB 24.90 on September 4, 2026. Based on consensus EPS, the current share price corresponds to forecast 2026/2027/2028 P/E ratios of approximately 10.9x, 9.8x and 8.9x; based on GJ Securities’ forecasts, approximately 12x, 10x and 9x; and based on Orient Securities’ forecasts, approximately 10.6x, 9.6x and 8.7x. Overall, the company’s valuation is relatively low, but part of this discount reflects market concerns over earnings pressure in 2026, M&A integration, Kunming Pharmaceutical’s business adjustment and the pace of recovery in the traditional CHC business. Institutional ratings are broadly positive, with recent target prices concentrated around RMB 33–37. The RMB 53.13 target represents an earlier and more optimistic DCF valuation. Valuation support mainly comes from prescription-drug growth, Tasly integration and brand-channel advantages. Key risks include a decline in CHC, Kunming Pharmaceutical’s adjustment, weaker-than-expected M&A integration, rising expense ratios and changes in pharmaceutical policies.

4. Recent News and Announcements

4.1 Controlling Shareholder Nominated Xing Jian for Director By-Election; Extraordinary General Meeting Approved the Proposal by a Large Margin

On September 2, 2026, the company disclosed an announcement concerning the nomination by controlling shareholder China Resources Pharmaceutical Holdings Company Limited of Xing Jian as a candidate for the ninth Board of Directors. Former director, vice president, general counsel and chief compliance officer Zhou Hui retired and stepped down, creating a vacancy on the Board. China Resources Pharmaceutical Holdings submitted the interim proposal on August 31, 2026. As of the announcement date, it held 1,052,142,679 China Resources Sanjiu shares, representing 63.22% of total share capital. At the second extraordinary general meeting of 2026 held on September 10, the proposal to elect Xing Jian as director was approved, with 1,081,269,228 shares, or 99.4914%, in favor; 5,130,662 shares, or 0.4721%, against; and 396,769 shares, or 0.0365%, abstaining. The approval rate among minority shareholders was 84.0497%. The matter concerns corporate governance and management adjustment and does not involve a change in control.

4.2 Kunming Pharmaceutical Approved to Register RMB 1 Billion in Medium-Term Notes

On September 2, 2026, the company disclosed that Kunming Pharmaceutical had received the Acceptance of Registration Notice from the National Association of Financial Market Institutional Investors. Kunming Pharmaceutical was approved to register the issuance of RMB 1 billion in medium-term notes. The registration quota is valid for two years from the date of the notice. Industrial Bank, China Merchants Bank and Bank of China will act as joint lead underwriters. Kunming Pharmaceutical may issue the notes in installments during the registration-validity period. The specific issue date, maturity and interest rate will depend on funding needs and market conditions. The matter had previously been approved by the China Resources Sanjiu Board and shareholders’ meeting on June 8 and June 26, 2026. The announcement indicates progress in the financing-registration process only; it does not mean that the full RMB 1 billion has been issued or raised. The actual issue amount, interest rate, maturity and specific use of proceeds have not been disclosed.

4.3 First-Half 2026 Results Briefing Disclosed R&D and Business Progress

On August 28, 2026, the company announced that it planned to hold its first-half 2026 results briefing on September 4, together with Kunming Pharmaceutical and Tasly Pharmaceutical Group. The investor-relations activity record dated September 4, 2026, showed that R&D expenditure was RMB 731 million in January–June 2026. The company had 55 innovative and improved new drugs under development, including 7 at the NDA/Pre-NDA stage and 21 in Phase II or Phase III clinical development. The jointly developed HiCM-188 project had entered confirmatory clinical trials. The marketing application for the weight-loss indication of jointly developed BGM0504 injection had been accepted by the Center for Drug Evaluation of the National Medical Products Administration, while a domestic Phase III trial for the type 2 diabetes indication was progressing. The company proposed continuing to focus on consumer health, medical health and senior health during the 15th Five-Year Plan period, building a “one core, two wings” business structure around China Resources Sanjiu, Kunming Pharmaceutical and Tasly. These are operating updates and strategic communications and do not constitute new orders or earnings commitments.

4.4 First-Half 2026 Dividend Proposal Approved by Shareholders

On August 22, 2026, the company disclosed a first-half 2026 distribution proposal to pay a cash dividend of RMB 4.15 per 10 shares, including tax, with no bonus shares and no capitalization of capital reserves. Based on total share capital of 1,664,217,858 shares as of June 30, 2026, the expected cash dividend was RMB 690,650,411.07, approximately 41.34% of first-half 2026 net profit attributable to shareholders of the listed company. The proposal was approved at the extraordinary shareholders’ meeting held on September 10, 2026, with 99.9373% of shares voting in favor. As of September 11, 2026, the company had not disclosed the specific record date, ex-dividend date or implementation schedule. The final distribution amount may change based on the number of shares entitled to the distribution before the record date.

4.5 Company and Subsidiaries Approved for Bank Wealth-Management Quotas of up to RMB 10 Billion

On August 22, 2026, the company disclosed a proposal to use no more than RMB 10 billion in total idle own funds to purchase wealth-management products from banks and bank wealth-management subsidiaries. The aggregate quota for China Resources Sanjiu and its other subsidiaries was no more than RMB 10 billion, Kunming Pharmaceutical’s quota was no more than RMB 2 billion, and Tasly Pharmaceutical Group’s quota was no more than RMB 4 billion. Products from China Resources Bank were excluded. The matter was approved at the extraordinary shareholders’ meeting on September 10, 2026, with 98.7438% of shares voting in favor. The quota is an arrangement for managing idle own funds and does not represent an actual investment amount or expected return. Actual wealth-management balances, product maturities and yields have not been disclosed.

4.6 Kunming Pharmaceutical to Conduct Non-Recourse Receivables Factoring as a Related-Party Transaction

On August 22, 2026, the company disclosed that Kunming Pharmaceutical and its subsidiaries planned to conduct non-recourse receivables factoring with China Resources Commercial Factoring. The purpose is to optimize the accounts-receivable structure, reduce related risks, accelerate cash turnover and improve capital efficiency. Related directors Bai Xiaosong, Yu Shutian and Liang Zhuqiang abstained from voting. The proposal was approved with 7 votes in favor, 0 against and 0 abstentions, and was approved by the independent directors’ special meeting. The research notes did not specify the transaction size, pricing or financing/factoring fees. The matter currently does not appear to constitute a material asset restructuring or change in control.

4.7 Shareholder and Control Dynamics

As of the announcement date of September 2, 2026, controlling shareholder China Resources Pharmaceutical Holdings held 63.22% of China Resources Sanjiu and nominated Xing Jian for the director by-election. The by-election was approved by shareholders on September 10, 2026. As of September 11, 2026, no change in the controlling shareholder or actual controller and no control-transfer arrangement had been identified. The Eastmoney individual-stock calendar showed 96,875 shareholders as of August 10, 2026, down 603 from the previous period; as of July 10, 2026, there were 102,032 shareholders, up 537 from the previous period. The latest verifiable shareholder count was dated August 10, 2026, rather than being real-time data as of September 11.

4.8 No New Buyback, Purchase or Significant-Shareholder Disposal Announcement Identified as of September 11, 2026

As of September 11, 2026, a search of public announcements found no new announcement in September 2026 concerning a China Resources Sanjiu share buyback, a purchase by the controlling shareholder or a disposal by a significant shareholder. The company’s first-half 2026 report did not show any ongoing share-repurchase arrangement involving centralized competitive bidding. This conclusion is based on public information available as of September 11, 2026; it does not mean that no future announcement will be made, nor does it exclude update delays on certain market-data platforms.

4.9 No Third-Quarter 2026 Earnings Preview or Major M&A Arrangement Identified

As of September 11, 2026, no formal earnings preview or earnings-warning announcement for the first three quarters of 2026 had been identified. The company’s disclosed first-half 2026 report showed operating revenue of approximately RMB 15.013 billion and net profit attributable to shareholders of approximately RMB 1.672 billion, down approximately 7.90% year on year. These figures belong to the interim report and are not a third-quarter earnings preview. As of the same date, no new announcement concerning a major M&A transaction, asset restructuring, share issuance for asset acquisition or control transaction in September 2026 had been identified.

4.10 Gegen Decoction Granules Approved for Marketing in Macao

On July 27, 2026, Gegen Decoction Granules, developed by the company and held by Sanjiu Health Tiandi (Macao) Co., Ltd., was approved for marketing by the Macao Pharmaceutical Administration and classified as an OTC drug. This is a product-registration and overseas-market expansion matter rather than a major M&A transaction, and it has some positive significance for the overseas promotion of classical formula products and TCM.

5. Share-Price Performance and Technical Analysis

5.1 Price Overview

5.2 Technical Indicators

As of September 11, 2026, China Resources Sanjiu closed at RMB 23.89, below the MA5, MA10 and MA20, indicating weak short-term technical momentum. Directional MACD information placed it below the zero axis or in a weak area, while the approximate RSI of 47 had not entered oversold territory. The share price was close to the lower Bollinger Band at RMB 23.65–23.70. RMB 23.65–23.90 formed the first support-monitoring zone, and RMB 24.45–24.55 the concentrated moving-average resistance zone. The September 11 decline was accompanied by higher turnover of approximately RMB 239 million and net extra-large-order outflows of approximately RMB 9.0059 million, indicating cautious short-term fund flows. The share price was in the lower portion of its 52-week range but remained some distance above the 52-week low of RMB 21.60.

5.3 Short-Term Outlook (Next Week, Scenario Analysis for Reference Only)

⚠️ Risk Warning: The following is a subjective scenario analysis based on closing data and historical prices and technical indicators as of September 11, 2026. It does not constitute investment advice or a single-point target-price forecast.

① Key Technical Levels

② Scenarios for the Next Week (Subjective Weights, Not Statistical Probabilities)

• Range-bound consolidation (relatively higher weight, approximately 60%; a subjective heuristic judgment based on the current technical structure and fund flows, not a statistical probability): Price range of RMB 23.65–24.60. Triggers include support near RMB 23.65–23.90, turnover remaining approximately RMB 120–250 million, no high-volume break below RMB 23.60 for two consecutive sessions and no clear systemic decline in pharmaceutical or TCM stocks. Under this scenario, the share price may fluctuate around RMB 24, with RMB 24.45–24.60 as the main resistance
• Weak decline (medium weight; a subjective heuristic judgment based on the current technical structure and fund flows, not a statistical probability): Price range of RMB 23.20–23.65. Triggers include a decisive close below the lower Bollinger Band around RMB 23.65, daily turnover expanding materially to above RMB 250–300 million while major funds continue to flow out, broad weakness in pharmaceutical stocks, or a failure to quickly recover after losing RMB 23.60. If RMB 23.20 is also broken on high volume, the RMB 22.60–22.90 area should be monitored
• Stronger rebound (low-to-medium weight; a subjective heuristic judgment based on the current technical structure and fund flows, not a statistical probability): Price range of RMB 24.60–25.05. Triggers include reclaiming the moving-average resistance zone at RMB 24.45–24.60, daily turnover increasing to approximately RMB 300 million or more on a rising day rather than a high-volume intraday reversal, consecutive net inflows from extra-large and large orders, and simultaneous strength in TCM and pharmaceutical stocks. A decisive recovery above RMB 24.60 would bring RMB 24.80–25.05 into view; failure to increase volume and a return below RMB 24.40 would weaken confirmation of the rebound

③ Funding and Liquidity Background

As of September 11, 2026, the turnover rate was 0.60% and turnover approximately RMB 239 million. Turnover over recent sessions was generally RMB 125–239 million. The latest disclosed turnover rates were approximately 0.30%, 0.31%, 0.40%, 0.53%, 0.45% and 0.60%; turnover expanded to approximately RMB 358 million on September 3, with a turnover rate of approximately 0.87%. The stock is a large-cap, low-turnover name. Daily turnover is generally below 1%, so short-term trend confirmation usually requires a significant expansion in turnover. Regarding the shareholder structure, as of June 30, 2026, the top 10 shareholders held approximately 68.6% in aggregate and the controlling shareholder held 63.22%, alongside institutional shareholders including public ETFs, insurance funds and Hong Kong Securities Clearing. However, these data are subject to quarterly or phase-based lags and cannot be used to determine real-time institutional holdings on September 11, 2026. High concentration and low turnover imply relatively limited freely tradable shares, meaning marginal changes in capital flows may have a relatively clear impact on the price. The shareholder data do not represent a real-time holding structure.

If turnover exceeds approximately RMB 280–300 million for two consecutive sessions and the closing price moves above RMB 24.60, this could be viewed as a signal of a material increase in short-term participation. If higher volume mainly occurs during declines, it should first be interpreted as the release of selling pressure rather than simply as capital inflows.

④ Points to Monitor (Observation Framework Only, Not Trading Instructions)

• Monitor whether the RMB 23.65–23.90 area stabilizes on lower volume; this is an observation framework, not a trading instruction.
• Monitor whether RMB 24.45–24.60 can be recovered and held, as this is the concentrated short-term moving-average resistance zone; this is an observation framework, not a trading instruction.
• If RMB 23.20–23.45 is broken with higher volume, monitor the risk of a decline toward RMB 22.60–22.90; this is an observation framework, not a trading instruction.
• If daily turnover expands continuously to approximately RMB 280–300 million or more and the share price rises above RMB 24.60, this may serve as a confirmation signal of improved short-term price-volume dynamics; this is an observation framework, not a trading instruction.

The above scenario analysis is based on closing data, historical prices and technical indicators as of September 11, 2026. Short-term share prices may also be affected by news, fund flows, broader market conditions and other factors. Technical indicators have inherent lag and limitations. This analysis does not guarantee future price performance or constitute a buy or sell recommendation. Investors should independently assess the latest market information and bear their own investment risks.

6. Industry Structure and Competitor Analysis

6.1 Industry Overview

China Resources Sanjiu operates in China’s TCM and OTC pharmaceutical industries, with businesses spanning branded OTC products, self-medication products, prescription drugs, TCM formula granules, decoction pieces, pharmaceutical distribution and consumer healthcare. Key competitive barriers include brands, channels, regulatory approvals, medicinal-material resources, quality systems and R&D platforms. The industry remains relatively fragmented overall, but competitive resources are concentrating among leading companies.

6.2 Competitive Landscape

• The Chinese patent-medicine and OTC markets contain numerous products, with relatively high homogeneity in certain categories. Consumers show brand preferences for common conditions such as colds, gastrointestinal disorders, dermatological conditions and orthopedic problems, making brands and channels important competitive barriers.
• Hospital medicines are affected by reimbursement lists, national and local volume-based procurement, DRG/DIP payment systems and rational-use policies. Generic drugs and certain traditional prescription drugs face pricing pressure. Branded OTC products have a certain degree of independent pricing power and brand premium in retail channels, but are affected by pharmacy traffic, online e-commerce and changes in consumer purchasing habits.
• Competitive barriers in TCM formula granules and decoction pieces arise from medicinal-material sources, quality standards, manufacturing processes, traceability systems, product registration and terminal coverage. Companies with medicinal-material bases, quality-control systems, production scale and hospital channels have greater advantages.
• Industry growth is shifting from extensive expansion to structural growth. Potential growth areas include aging and chronic-disease management, long-term demand for cardiovascular, cerebrovascular and respiratory medicines, consumption upgrades in branded OTC products, formula granules and premium decoction pieces, classical formulas, innovative TCM and natural medicines, online retail and O2O, and the internationalization and overseas registration of TCM.
• Public industry research commonly lists Yunnan Baiyao, Guangzhou Baiyunshan, China Resources Sanjiu, Beijing Tongrentang, Tasly and Buchang Pharmaceutical among the major TCM companies. However, market-share and ranking methodologies differ by institution and should not be directly equated.

6.3 Major Competitors

Compared with peers, China Resources Sanjiu’s core differentiators are its mass-market OTC brands such as “999,” nationwide retail and hospital channels, a broad household-medicine portfolio, and capabilities in Chinese medicinal-material quality control, formula granules and scaled intelligent manufacturing. Yunnan Baiyao is more focused on healthcare and personal care, Baiyunshan is more diversified, Tongrentang emphasizes traditional premium Chinese medicine, Tasly has relatively visible product-mix and earnings volatility, and Jiangzhong focuses on gastrointestinal products. Industry rankings and competitor classifications vary by statistical methodology; the market share or ranking reported by any single institution should not be treated as definitive.

7. Risk Factors

• CHC business decline: First-half 2026 CHC self-medication revenue was approximately RMB 6.132 billion, down 23.29% year on year. This business accounted for 47.82% of the company’s 2025 operating revenue. If traditional OTC and self-medication products recover more slowly than expected, revenue, brand-investment efficiency and overall earnings growth will be directly affected.
• M&A integration: After Tasly entered the controlling scope in 2025, revenue growth accelerated, but net profit attributable to shareholders grew only 1.58% in 2025 and declined 7.96% year on year in the first half of 2026. If Tasly and Kunming Pharmaceutical underperform expectations in business, channel, R&D or management synergies, margins and returns on capital may remain under pressure.
• Prescription-drug policy and pricing: Prescription drugs accounted for 38.27% of 2025 operating revenue and are sold to hospitals and primary medical terminals. They may be affected by medical-insurance cost controls, national and local volume-based procurement, DRG/DIP payment systems and rational-use policies. Price reductions or access changes could weaken product profitability.
• Raw-material and Chinese medicinal-material costs: Raw materials accounted for 68.91% of pharmaceutical-industry operating costs in 2025. Chinese medicinal materials are subject to seasonality, origin differences and price volatility. Although the company has cultivation, origin-processing, strategic-reserve and traceability capabilities, it is not an absolute price setter. Raw-material price increases or quality fluctuations could compress gross margin.
• Accounts receivable and working capital: At the end of 2025, the carrying value of accounts receivable was RMB 8.164 billion, approximately 25.8% of 2025 operating revenue, mainly reflecting settlement with pharmaceutical distributors, hospitals and terminals. Longer collection periods or rising bad-debt risk could increase capital occupation and affect operating cash flow.
• R&D investment and commercialization uncertainty: R&D expenditure was RMB 731 million in the first half of 2026, with 55 innovative and improved new drugs under development. However, projects remain at different clinical and application stages. Projects such as BGM0504 have not yet generated confirmed incremental earnings, creating risks of R&D failure, approval delays and weaker-than-expected commercialization.
• Low-margin distribution business: Pharmaceutical and medical-device wholesale and retail generated revenue of RMB 3.897 billion in 2025, with a gross margin of only 14.29%. Profitability depends more on scale, turnover and capital management. Higher channel expenses, promotional investment, payment terms or funding costs could weaken overall earnings quality.
• Technical and market-liquidity risk: As of September 11, 2026, the share price was below short-term moving averages, MACD was below the zero axis or in a weak area, and extra-large orders recorded net outflows of approximately RMB 9.0059 million. If support near RMB 23.65 fails on higher volume, the share price could test RMB 23.20–23.45 or lower. Technical indicators are lagging and cannot represent changes in fundamentals.

8. Conclusion and Outlook

The company’s medium- and long-term growth drivers mainly include the channel foundation of branded OTC and consumer healthcare products, prescription-drug expansion, business synergies between Tasly and Kunming Pharmaceutical, and structural opportunities in formula granules, premium decoction pieces, senior healthcare and innovative-drug R&D. Institutional average forecasts indicate net profit attributable to shareholders of approximately RMB 3.650 billion, RMB 4.058 billion and RMB 4.463 billion in 2026–2028, respectively. However, these forecasts are aggregated sell-side estimates with considerable range differences, and actual delivery will depend on CHC recovery, the quality of prescription-drug growth and M&A integration efficiency.

Near-term earnings remain in an adjustment phase. In the first half of 2026, prescription-drug growth did not fully offset the decline in CHC. Net cash flow from operating activities fell 15.29% year on year, while the sizable accounts-receivable balance tied up working capital in pharmaceutical distribution, hospitals and terminal settlements. Kunming Pharmaceutical’s financing arrangements, related-party factoring and wealth-management quota may support capital management, but capital-use efficiency, financing costs, related-party-transaction transparency and post-integration earnings quality should be monitored continuously.

Overall, the company has advantages in brands, channels, manufacturing and TCM value-chain synergies, while its valuation already reflects some concerns regarding earnings pressure and integration uncertainty. Key areas to monitor are whether CHC revenue can stabilize, whether prescription-drug growth can translate into sustainable profit, whether Tasly and Kunming Pharmaceutical synergies improve overall returns, and whether the share price can reclaim the RMB 24.45–24.60 resistance zone or break below RMB 23.65 support on higher volume. These observations do not constitute buy or sell recommendations.

Data Sources

• https://www.999.com.cn/annualReport/2026-03-23/48711d30-5d19-4e0d-a66b-895add7a12b8.pdf
• China Resources Sanjiu (000999)_Company Announcements_China Resources Sanjiu: 2025 Annual Report_Sina Finance_Sina.com
• Formula Granules—Welcome to China Resources Sanjiu
• China Resources Sanjiu (000999)_Company Announcements_China Resources Sanjiu: 2025 Annual Report_Sina Finance_Sina.com
• China Resources Sanjiu 2024 Visual Annual Report|Shanghai Securities News·China Securities Network
• China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Full Text of the 2025 Annual Report
• China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Full Text of the 2026 Interim Report
• China Resources Sanjiu (000999) Earnings Forecast_F10_Tonghuashun Financial Services
• China Resources Sanjiu (000999) Earnings Forecast_F10_Tonghuashun Financial Services
• China Resources Sanjiu (000999) Stock Information—Data Platform
• China Resources Sanjiu (000999)_Company Announcements_China Resources Sanjiu: Summary of the 2026 Interim Report_Sina Finance_Sina.com
• China Resources Sanjiu (000999) P/E|Valuation|Fundamentals—Lixinger
• Citic Bank International
• China Resources Sanjiu (000999)—Historical Trading Data | Dabanke
• https://www.kuaikuaixuan.com/gupiao/buy/buy1.php?id=38&utm_source=openai
• China Resources Sanjiu (000999) Stock Price Trends, Technical Analysis, Forecasts and Buy/Sell Suggestions—Investing.com
• China Resources Sanjiu (000999)_Capital Flows_Stockstar
• China Resources Sanjiu (000999)_Stock Quotes_Stockstar

This report was automatically searched, compiled and generated by AI based on publicly available information. The information is current through the September 11, 2026 close; September 12–13, 2026 were weekend market holidays. Information may differ in timeliness, and specific data should be based on the company’s formal announcements and authoritative data terminals. This report is for information organization and research reference only and does not constitute investment advice. Investors should make independent judgments and bear their own investment risks.